Choose Language
Select a language for news translation.
Royalty Pharma will hold a Q2 2026 earnings conference call on August 5, 2026, at 8:00 AM ET to discuss financial results and future strategies. This event is …
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbust…
Astellas Pharma's net income rose to 141.81 billion yen in Q1, up from 68.42 billion yen last year, reflecting strong demand and operational efficiencies. For …
Merck reported a $1.34 billion net loss in Q2 2023, prompting a cut in profit guidance due to $14.7 billion in acquisition-related charges, despite raising its…
Written by Eric Volkman for The Motley Fool -> The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.…
Written by Brendan Coffey for The Motley Fool -> 20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acqui…
On Friday, Ionis Pharmaceuticals' Director, Michael R. Hayden, made a $1.06M buy of IONS, purchasing 20,000 shares at a cost of $52.94 a piece. Ionis Pharmaceu…
The VanEck Pharmaceutical ETF (PPH) fell 1.8% on Monday, driven by a 7.2% drop in AstraZeneca and a 4.6% decline in Axsome Therapeutics. This downturn reflects…
Tilray Brands achieved an 11% revenue increase for fiscal 2026, primarily due to a 21% growth in its distribution business, which generated over $327 million. …
Japanese pharmaceutical giant Eisai reported a significant surge in first-quarter earnings, with net income attributable to parent company owners climbing 26% …
Written by Keith Noonan for The Motley Fool -> Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The comp…
